Galectin Therapeutics Inc reports results for the quarter ended in January - Earnings Summary

Galectin Therapeutics

15/05/2024 16:08

* Galectin Therapeutics Inc  GALT.OQ  reported a quarterly
adjusted loss of 19 cents​​ per share for the quarter ended in
January, identical to the same quarter last year.  The lone
analyst forecast for the quarter was for a loss of 16 cents per
share. 
    * Reported revenue was zero​; analysts expected zero. 
    * Galectin Therapeutics Inc's reported EPS for the quarter
was a
loss of 19 cents​.
    * The company reported a quarterly loss of $11.5 million.
    * Galectin Therapeutics Inc shares had risen by 18.8% this
quarter and gained 71.1% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Galectin
Therapeutics Inc is $11.00 
This summary was machine generated from LSEG data May 15 at
03:08 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2024      -0.16          -0.19          Missed
 Dec. 31 2023      -0.16          -0.16          Met
 Sep. 30 2023      -0.16          -0.24          Missed
 Jun. 30 2023      -0.21          -0.15          Beat